Darbepoetin alfa

Drug Profile

Darbepoetin alfa

Alternative Names: Aranesp; Darbepoetin-α; KRN-321; Nesp; Nespo; Novel erythropoiesis stimulating protein

Latest Information Update: 17 Nov 2016

Price : $50

At a glance

  • Originator Kirin-Amgen
  • Developer Amgen; Kirin-Amgen; Kyowa Hakko Kirin
  • Class Antianaemics; Recombinant erythropoietins
  • Mechanism of Action Erythropoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Anaemia
  • Phase III Breast cancer

Most Recent Events

  • 21 Oct 2016 Preregistration for Anaemia (In patients with renal failure) in Indonesia (SC) (Kyowa Hakko Kirin pipeline, October 2016)
  • 21 Oct 2016 Kirin Amgen files applications for Anaemia (In patients with myelodysplastic syndromes) in Malaysia, Hong Kong and Singapore (Kyowa Hakko Kirin pipeline, October 2016)
  • 16 Jun 2016 Aggen withdraws a phase I trial in Anaemia in Finland due to difficulty in enrolment (NCT01428154)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top